Podcasts about AstraZeneca

This episode of GEN's Touching Base spotlights the unexpected relationship between breathing low oxygen and restoration of neuron function in a mouse model of Parkinson's disease. In addition, a single gene therapy injected at birth now offers lasting protection from HIV in infant rhesus macaques. Rounding out our episode, we discuss key factors shaping this year's A-List of Top 10 U.S. Biopharma Clusters and recap the regulatory conflict surrounding Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy, Elevidys®—including the departure of Vinay Prasad, MD, the FDA official behind the agency's brief get-tough approach.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base:GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in MiceGEN, August 6, 2025Out of Thin Air: Hypoxia Reverses Parkinson's Symptoms in MiceBy Fay Lin, PhD GEN, August 6, 2025Early Gene Therapy Provides Lasting HIV Protection in Newborn PrimatesGEN, July 30, 2025StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT StocksBy Alex Philippidis, GEN Edge, August 3, 2025Sarepta to Resume Shipping DMD Gene Therapy to Ambulant PatientsBy Alex Philippidis, GEN Edge, July 28, 2025Sarepta Under Scrutiny, AstraZeneca's Big Bet, and AI vs. IDRsBy Alex Philippidis, Uduak Thomas, Fay Lin, PhD, Corinna Singleman, PhD, GEN, July 25, 2025About Face: Sarepta to Pause Elevidys Shipments TemporarilyBy Alex Philippidis, GEN Edge, July 21, 2025Touching Base PodcastHosted by Corinna Singleman, PhDBehind the BreakthroughsHosted by Jonathan D. Grinstein, PhDThe State of Biotech Summit Registration Hosted on Acast. See acast.com/privacy for more information.

“Seeing that you can get through the most difficult times in life, succeed, and then also return to your community and work in service to your community was a lesson that has stuck with me,” says Dr. Uche Blackstock, the Founder and CEO of Advancing Health Equity and our guest on this inspiring episode of Raise the Line with Osmosis from Elsevier. It was a lesson the Harvard-trained physician learned from her own mother – also a Harvard trained physician – who overcame poverty, sexism and racial bias to forge an inspiring path.  In her bestselling book, Legacy: A Black Physician Reckons with Racism in Medicine, Dr. Blackstock weaves her mother's remarkable story with her own and argues for systemic change in a healthcare system riddled with racially-biased practices and policies that impact patient outcomes. As she explains to host Lindsey Smith, Advancing Health Equity's work to drive measurable and sustainable change is focused on embedding equity as a core value in the leadership, strategy, and organizational practice of health systems. “We exist to challenge inequities, empower underrepresented communities, and help build a healthcare system where everyone can thrive.” Don't miss a thought-provoking conversation with a nationally respected voice that also addresses race correction factors that impact the care of Black patients, and the work required of health institutions to build trust in effected communities.Mentioned in this episode:Advancing Health EquityLegacy: A Black Physician Reckons with Racism in Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

This Day in Legal History: Gulf of Tonkin ResolutionOn August 7, 1964, the U.S. Congress passed the Gulf of Tonkin Resolution, dramatically reshaping the legal landscape of American military engagement. Prompted by reports—later disputed—of North Vietnamese attacks on the USS Maddox in the Gulf of Tonkin, the resolution granted President Lyndon B. Johnson broad authority to use military force in Southeast Asia without a formal declaration of war. It passed nearly unanimously, with only two dissenting votes in the Senate, reflecting the tense Cold War atmosphere and congressional trust in the executive branch.Legally, the resolution functioned as an open-ended authorization for the president to escalate military operations in Vietnam. Within months, it led to the deployment of hundreds of thousands of U.S. troops. Critics would later argue that it allowed the executive to bypass Congress's constitutional war-making powers, effectively green-lighting a years-long conflict based on contested facts.As the war dragged on and public opinion turned, the resolution became a focal point for debates over separation of powers, congressional oversight, and executive overreach. In 1971, amid growing backlash, Congress repealed the resolution, but its legacy endured. It served as a legal and historical precedent for future authorizations of force, including those passed after 9/11.A federal appeals court has upheld the SEC's long-standing “gag rule,” which prevents defendants who settle civil enforcement cases from publicly denying the agency's allegations. The 9th Circuit Court of Appeals ruled 3-0 that the rule is not unconstitutional on its face but left room for future challenges depending on how it's applied. The policy, in place since 1972, requires settling parties to at least refrain from admitting or denying wrongdoing. The court emphasized that defendants remain free to reject settlements if they wish to speak out.Twelve petitioners, including former Xerox CFO Barry Romeril and the New Civil Liberties Alliance (NCLA), challenged the SEC's January 2024 decision not to revise the rule. Romeril had previously brought a similar challenge to the Supreme Court with support from Elon Musk, but the Court declined to hear it. Writing for the panel, Judge Daniel Bress noted that removing the gag could reduce the SEC's ability to settle cases efficiently and that speech restrictions are voluntary components of settlement agreements.The NCLA criticized the decision, arguing it effectively sanctions government-imposed silence and announced plans to pursue further appeals. SEC Commissioner Hester Peirce also dissented from the agency's refusal to revisit the rule, arguing that it hinders public accountability by suppressing potential criticism. The SEC declined to comment on the ruling, which came in the case Powell et al v. SEC.US appeals court upholds SEC 'gag rule' over free speech objections | ReutersThe Stanford Daily, Stanford University's student newspaper, has filed a lawsuit against the Trump administration, accusing it of violating the free speech rights of foreign students. The suit, filed in federal court in California, alleges that threats of arrest, detention, or deportation have created a climate of fear among international students, discouraging them from writing about sensitive political issues—particularly the Israeli-Palestinian conflict. Two unnamed students joined the paper in the lawsuit, which names Secretary of State Marco Rubio and Secretary of Homeland Security Kristi Noem as defendants.According to the plaintiffs, the administration has labeled pro-Palestinian viewpoints as antisemitic or extremist and attempted to deport students expressing such views, framing them as threats to U.S. foreign policy. In some instances, students have been detained without charges, though judges have later ordered their release. The lawsuit contends that these actions have led to widespread self-censorship among international students, chilling constitutionally protected speech in areas such as protests, slogans, and commentary on U.S. and Israeli policy.The Stanford Daily is seeking a court ruling affirming that the First Amendment protects non-citizens from government retaliation based on their speech. The university clarified it is not involved in the suit, as the newspaper operates independently. Attorney Conor Fitzpatrick, representing the paper, called the government's actions antithetical to American values of free expression.Stanford student newspaper sues Trump administration for alleged free speech violations | ReutersA U.S. appeals court has reinstated a lawsuit accusing major drugmakers Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to limit drug discounts provided under the federal 340B program. The 2nd Circuit Court of Appeals reversed a lower court's dismissal, allowing two health clinics—Mosaic Health and Central Virginia Health Services—to proceed with their proposed class action. These clinics claim the companies colluded in 2020 to restrict discounts on diabetes medications, harming safety-net providers and the low-income patients they serve.The court found that because the four companies control much of the diabetes drug market, coordination to limit discounts could be feasible. Judge Myrna Pérez, writing for the panel, noted the allegations were plausible enough to move forward. The drugmakers have denied wrongdoing and argue their policies were developed independently to address alleged fraud in the 340B program. Sanofi and Novo Nordisk said they are reviewing the decision, while Lilly criticized the ruling and defended its practices as legal.The clinics say the drugmakers earned billions in extra profits through these policies, which allegedly undercut essential savings for providers. The case underscores the broader tension between pharmaceutical companies and healthcare providers over the administration of the 340B program, which requires drugmakers to offer discounts in exchange for access to federal healthcare funds.US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies | ReutersPepsiCo is facing a proposed class action lawsuit alleging it engaged in illegal price discrimination by giving more favorable pricing and discount terms to large retailers like Walmart while denying the same deals to smaller businesses. Filed in federal court in Manhattan by an Italian restaurant operator, the lawsuit claims this practice violates the Robinson-Patman Act, a rarely enforced 1936 antitrust law meant to prevent discriminatory pricing that harms competition.The suit accuses Pepsi of providing payments and allowances to Walmart that were not extended to other retailers, placing smaller businesses at a competitive disadvantage. Although Walmart is named in the allegations, it is not a defendant in the case. The plaintiff argues that Pepsi's pricing tactics unfairly burden other merchants who must pay more for the same products.This legal action echoes a previous Federal Trade Commission (FTC) lawsuit filed against Pepsi in January under the Biden administration. However, the second Trump administration dropped the case in May, with Trump-appointed FTC Chair Andrew Ferguson criticizing it as a politically motivated effort launched too late in the prior administration's term. The FTC has not commented on the new private lawsuit.The class action seeks unspecified damages on behalf of thousands of Pepsi purchasers nationwide. Neither Pepsi nor Walmart has publicly responded to the allegations.Pepsi accused of price discrimination in new merchant class action | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Sue Norfolk, manager of the Schroder Income Growth Trust, shares how UK companies are adapting their capital distribution strategies with a shift towards share buybacks and stable dividend growth. We also cover the evolving landscape of domestic versus international opportunities, sector-specific insights into financials, consumer discretionary, and industrials, and how geopolitical tensions are factored into portfolio decisions. Finally, we examine the fund's bottom-up stock selection approach, recent adjustments in holdings like AstraZeneca, GSK, and Burberry, and the current valuation-driven opportunities in the market.What's covered in this episode:Schroder Income Growth's dividend hero statusDividends, share buybacks or social dividends?How volatility is factored into the portfolioStaying focused on bottom-up stock pickingThe impact of US politics on the trustRight and wrong tariff callsThe attractive nature of UK mid-capsA closer look at financials and customer discretionaryMaking calls on defence and industrialsWhy this manager favours AstraZeneca over GSKDoubling down on BurberryWhy UK equity is still attractive todayMore about the trust: Launched in 1995, the Schroder Income Growth Trust's principal aim is to provide real growth of income in excess of the rate of inflation. It invests mainly in the shares of UK larger and medium-sized companies, although it can also invest some of the portfolio in the shares of firms listed abroad.Learn more on fundcalibre.comPlease remember, we've been discussing individual companies to bring investing to life for you. It's not a recommendation to buy or sell. The fund may or may not still hold these companies at the time of listening. Elite Ratings are based on FundCalibre's research methodology and are the opinion of FundCalibre's research team only.

This week on Careers in Discovery, we're joined by Martin Brenner, CEO and CSO of iBio and one of Biotech's most experienced R&D leaders. Martin shares his journey from pharmacologist to global R&D executive, with leadership roles at Pfenex, Recursion, AstraZeneca, and Stoke Therapeutics. Now at iBio, he leads a company developing gene therapies for rare diseases - while applying lessons from decades of drug development to a new generation of science. We talk about the power of simplicity in communication, why leaders need to create space for science to breathe, and how to build R&D teams that are lean, smart, and focused on what matters most.

In this second episode of a two-part series, Craig is joined by Steffen Schad (Head of Outbound Product Management, SAP BTP), Richard Henry (Commercial Director, Bluestonex), and Glenn van der Meijden (Senior Director, SAP Platform, AstraZeneca) to explore the key findings of UKISUG's latest SAP BTP Research Paper.In this episode, they delve into the evolving BTP skills landscape, the importance of internal capability, and how customers are balancing innovation with governance. They explore practical training paths, effective credit management, and how to build compelling business cases by linking BTP to real-world value. The discussion also highlights honest user perspectives and tips for getting the most from your BTP investment.You can download the UKISUG BTP Research Paper here: https://www.sapusers.org/resource/sap-btp-research-paper.htmlTo learn more about the UKISUG referral scheme, visit: https://www.sapusers.org/community-referral-schemeSAP documents mentioned by Steffen:SAP Integration Suite WhitepaperSAP BTP Guidance Framework 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

In the fascinating world of Pharma, a visionary and pragmatic man, @Marc de Garidel, stands out. His journey began in a down-to-earth family, setting the stage for an extraordinary adventure.Careers are rarely planned, but his appetite for adventure emerged early:He launched Amgen in Europe.He developed Ipsen in the United States.These initial steps marked the commencement of an incredible journey in the pharmaceutical world, teaching him how Pharma truly operates, especially regarding access today.Then, he embarked on a more entrepreneurial path as the CEO of biotechs:Corvidia Therapeutics, sold to Novo Nordisk in August 2020.CinCor Pharma, sold to AstraZeneca in February 2023.Currently, he is the CEO of Abivax.This experience taught him that taking risks fuels innovation, and every failure is a step towards success.Today, as the CEO of Abivax, Marc shares his wealth of experience with the Pharma community. His story is an invitation to embrace the unknown, confront challenges with courage, and see every opportunity as a new adventure.Marc encourages bold minds to pursue their passions, dare to take risks, and view every obstacle as a step towards success.Marc is a passionate individual, a grounded soul unafraid to dream big for patients.His legacy serves as a timeless reminder that adventure, wisdom, and courage constitute a potent trio for those aspiring to push the boundaries of medical innovation.-Update since the recording of the episode:This interview took place in August 2023. In October, Abivax entered the Nasdaq. Despite a challenging stock market context, this is the largest IPO in the history of a French biotech.

“Pandemics are a political choice. We will not be able to prevent every disease outbreak or epidemic but we can prevent an epidemic from becoming a pandemic,” says Dr. Joanne Liu, the former International President of Médecins Sans Frontières/Doctors Without Borders and a professor in the School of Population and Global Health at McGill University. You are in for a lot of that sort of frank and clear-eyed analysis in this episode of Raise the Line from Dr. Liu, whose perspective is rooted in decades of experience providing medical care on the frontlines of major humanitarian and health crises across the globe, as well as wrangling with world leaders to produce more effective responses to those crises and to stop attacks on medical facilities and aid workers in conflict zones. Firsthand accounts from the bedside to the halls of power are captured in her new book Ebola, Bombs and Migrants, which focuses on the most significant issues during her tenure leading MSF from 2013-2019.  The book also contains insights about the geopolitical realities that hamper this work, including lax enforcement of international humanitarian law, and a focus on national security that erodes global solidarity. Join host Lindsey Smith as she interviews this leading voice on our preparedness to meet the needs of those impacted by violent conflict, forced migration, natural disasters, disease outbreaks and other grave challenges. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

What do F1-linked scandals, Ponzi schemes, and popcorn-serving robot dogs have in common? Hosted by Michelle Martin with Ryan Huang, today’s Market View dives into Hotel Properties Limited (HPL) and its Orchard Road asset play, and the fallout from Envy Asset Management’s billion-dollar nickel scam. We also unpack shifting US trade policy under President Trump and its implications for Singapore, with the 10% tariff still looming. In our corporate roundup, we dissect the latest from AstraZeneca, Merck, Novo Nordisk, UOB’s United Overseas Insurance, and First REIT. Finally, we marvel at Unitree, UBTech Robotics, and Agibot at China’s AI Summit. From legal woes to leaping robot dogs—don’t miss today’s episode.See omnystudio.com/listener for privacy information.

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug.  Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week.    Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.”   On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year.   In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike.   And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.  

A huge morning of earnings and deal news: Carl Quintanilla, Sara Eisen, and David Faber kicked off the hour with better-than-expected consumer data – along with a First On CNBC interview with the CEOs of Union Pacific and Norfolk Southern as they sign a new deal for the largest buyout EVER in the industry – and become the first coast-to-coast freight operator in the US…  On the earnings front: hear from one analyst who calls Boeing a buy on new numbers there, more on how to navigate consumer-facing stocks after a slew of mixed reports out of travel and retail, and what's ahead for pharma on the tariffs front according to the CEO of AstraZeneca, as shares gain following strong results… Plus: what's driving Novo Nordisk shares to their worst day since 1987. Squawk on the Street Disclaimer

AstraZeneca may sell some of its medicines directly to patients in the US, according to Chief Executive Officer Pascal Soriot. AstraZeneca is looking to the US for growth, with Soriot saying the company will be self-sufficient in the US in a couple of months. He speaks with Bloomberg's Carol Massar, Tim Stenovec, and Madison MullerSee omnystudio.com/listener for privacy information.

Der er fuld drøn på nyhedsstrømmen fra finanssektoren, hvor tirsdag bl.a. byder på friske regnskabstal fra den svensk-britiske medicinalgigant, AstraZeneca. Millionærklubben ser på tallene sammen med adm. direktør i investeringsfonden Global Health Invest, Claus Johansen. Nyt er der også på energifronten med den netop indgåede rammeaftale for handel og investeringer mellem Europa og USA. Hvad det får af betydning for råvaremarkederne, spørger vi chefanalytiker hos Global Risk Management, Arne Lohmann Rasmussen, om. Med i studiet er chefanalytiker Lau Svenssen fra Svenssen & Tudborg, der tjekker ind på dagens aktuelle marked og samler op på gårsdagens relativt upopulære udmelding fra Bavarian Nordic.Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

APAC stocks traded with a mostly negative bias after a similar performance among global peers.European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 0.2% after the cash market closed with gains of 0.3%.FX markets are contained, EUR/USD sits on a 1.15 handle, USD/JPY maintains its footing above the 148 mark.Bund futures lacked direction overnight. Crude futures were little changed but held on to most of the prior day's spoils.Looking ahead, highlights include Spanish GDP Estimate, US Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from UK, Germany & US.Earnings from AstraZeneca, Barclays, Unite, L'Oreal, Air Liquide, Orange, Kering, Banca Generali, Terna, Endesa, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

We love to hear from our listeners. Send us a message. On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing  a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In episode 128 of Nonprofit Mission: Impact, Michael Randel joins Carol to explore how psychological safety—often dismissed as a “soft” concept—plays a critical role in nonprofit team performance, learning, and innovation.  They discuss:  The connection between organizational readiness and the deeper human dynamics that shape effective leadership and collaboration.  What psychological safety looks like in action,  Why it's vital in today's polarized climate, How nonprofit leaders can foster inclusive, high-trust environments where people feel safe to speak up, take risks, and learn from mistakes.   Episode highlights: [00:08:55] 

*This podcast episode was originally a YouTube LIVE with Q&A which you can watch on my YouTube channel here. This is a series of episodes I am doing on non-traditional careers running from July to December 2025. Sign up to my shared Google Calendar here so you never miss an episode*In this episode of Pharmacist Diaries, I'm joined by Adam Quicaro, a pharmacist who transitioned into the world of clinical development at Alexion Pharmaceuticals, the rare disease arm of AstraZeneca. This conversation kicks off our brand-new series exploring non-traditional pharmacy careers — and Adam's story is the perfect place to start.Adam walks us through his journey from working in an independent community pharmacy during high school to landing a fellowship in medical affairs, and eventually finding his true calling in clinical development. He shares how his childhood curiosity and love for science led him to pharmacy, but how it was a blend of strategic thinking, innovation, and a desire to solve complex problems that pulled him toward the pharmaceutical industry.We explore the differences between medical affairs and clinical development, what a typical day looks like in his role, and why pharmacists are uniquely positioned to succeed in the pharma space — especially those with a strong foundation in therapeutics, pharmacology, and patient care.Adam also opens up about the realities of salary expectations, comparing entry-level roles and fellowships, and highlighting the long-term rewards of working in industry. He talks about the benefits of hybrid working, generous leave policies, and how this role supports him not just as a pharmacist, but as a new dad seeking balance and fulfillment.If you've ever wondered what it's like to work behind the scenes of a clinical trial, or if you're curious about how to pivot out of a traditional role, this episode is full of honest, practical advice and inspiration. Whether you're a student or seasoned pharmacist, Adam's story will get you thinking about what's possible.JOIN MY NEWSLETTER COMMUNITY:This isn't your typical pharmacy newsletter - it's a weekly mentoring session delivered straight to your inbox, packed with actionable insights for ambitious pharmacy students. Each week, I share:Building multiple income streams while maintaining clinical practiceTime management secrets and productivity hacks I swear by ⚡Systems and strategies that keep it all running smoothly ⚙️Personal reflections on growth, failure, and resilienceBehind-the-scenes looks at podcast production and brand buildingIf you are ready to think differently about your future in pharmacy, sign up

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Change has been a theme in political news over the past few days. Politics analyst Jeff Schapiro and Michael Pope recap the week in politics and state government.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBCSERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancerINAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancerPresenters:Kevin Kalinsky, MD, MS, FASCO​Professor of Medicine​Louisa and Rand Glenn Family Chair in Breast Cancer Research​Winship Cancer Institute​Emory UniversityAtlanta, Georgia​Sara M. Tolaney, MD, MPH​Chief, Breast Oncology​Dana-Farber Cancer Institute​Associate Professor of Medicine​Harvard Medical School​Boston, Massachusetts​Content based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.Link to full program: https://bit.ly/4lFS4BC

“As parents dedicated to getting a treatment for our children in their lifetimes, we have turned the rare disease drug development landscape upside down and created a new model,” says Nicole Johnson, co-founder and executive director of the FOXG1 Research Foundation.  That's not an exaggeration, as the foundation is on track to make history as it begins patient clinical trials on a gene replacement therapy next year. The former TV news producer and media executive unexpectedly entered the world of patient advocacy and drug research after her daughter, Josie, was born with FOXG1, a genetic disorder which causes severe seizures and impedes normal movement, speech, and sleep among other problems. Johnson is also making an impact in another important dimension of the rare disease space in her efforts to educate parents, teachers, and students about disability inclusion through her Joyfully Josie book series and “Live Joyfully” education programs. Tune-in to this fascinating Year of the Zebra conversation with host Lindsey Smith to find out how the foundation is aiming to bring a drug to market in less than half the time and at a fraction of the cost than the industry standard, and how this model might impact research on other rare disorders. Mentioned in this episode:FOXG1 Research FoundationJoyfully Josie Book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Virginia sees "alarming" rise in child drownings; Maymont celebrates 100 years; AstraZeneca announces new facility.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has initiated a voucher program to address lower drug prices and boost domestic investment, with up to five companies being selected based on national priorities. Roche has halted shipments of Sarepta's Elevidys gene therapy after reports of patient deaths. Sarepta is under FDA scrutiny following a third patient death, while the agency welcomes a new top drug regulator and rejects multiple new drugs from entering the market. Insights from women in biopharma highlight the importance of resilience. Zhen Li, an engineer, is playing a crucial role in shaping the field of siRNA. Research suggests that GLP-1s may offer protection against neurodegenerative diseases. Dispatch Bio enters the scene with a substantial $216 million investment for universal CAR T therapy. Sarepta complies with an FDA request to suspend US shipments of Elevidys, raising concerns about transparency and impacting the company's reputation. Replimune experiences a significant drop in stock value following an FDA rejection, while AstraZeneca makes a bold $50 billion investment in US manufacturing to prepare for potential tariffs. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics has halted the distribution of Elevidys in the US after the FDA request, following two deaths. The company's transparency has been called into question, affecting its stock value. Replimmune also faced setbacks after the FDA rejected its melanoma treatment, causing a significant drop in shares. On a more positive note, AstraZeneca has pledged $50 billion for US manufacturing, focusing on drugs like Baxdrostat and oral glp-1 therapies. Sanofi has made a $1.6 billion vaccine acquisition, while Biogen commits $2 billion to expand US drug production. The pharmaceutical industry is seeing various developments and challenges, with companies adapting to regulatory demands and market pressures.

From the BBC World Service: Drugmaker AstraZeneca says it'll invest $50 billion in the United States by 2030, its biggest-ever manufacturing investment in the country. The AngloSwedish firm plans to build a major new site in Virginia, the latest in a string of big pharma bets on the U.S. as President Donald Trump threatens steep tariffs on drug imports. Plus, a bike shop boss reflects on business during the Tour de France.

From the BBC World Service: Drugmaker AstraZeneca says it'll invest $50 billion in the United States by 2030, its biggest-ever manufacturing investment in the country. The AngloSwedish firm plans to build a major new site in Virginia, the latest in a string of big pharma bets on the U.S. as President Donald Trump threatens steep tariffs on drug imports. Plus, a bike shop boss reflects on business during the Tour de France.

Plus: China confirms it will hold a top-level summit with the European Union in Beijing this week. And, AstraZeneca plans to invest $50 billion in the U.S. by 2030. Kate Bullivant hosts.  Sign up for WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The pharmaceutical giant Astra Zeneca has announced it's to invest $50bn in the US by 2030 as President Trump threatens the sector with tariffs.At a collapsed gold mine in the Democratic Republic of Congo people are using their hands and basic tools to try to reach victims who are trapped underground. And Andrew Peach looks at the rise of ride hailing apps in Thailand and the impact it's having on taxis and Tuk-Tuks.You can contact us on WhatsApp or send us a voicenote: +44 330 678 3033.

The White House maintains pressure on Federal Reserve Chairman Jerome Powell to cut interest rates but markets appear sanguine. The S&P 500 closes at a fresh record high while Treasury Secretary Scott Bessent tells our colleagues Stateside that he intends to investigate the Fed's decision-making. Brussels is reportedly preparing a range of ‘nuclear options' should the EU fail to agree a trade deal with Washington ahead of President Trump's August 1st deadline. Anglo-Swedish drug firm AstraZeneca says it will invest around $50bn for manufacturing and R&D in the US over the next five years as it braces for potential pharma tariffs.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUA865. CME/MOC/AAPA/IPCE credit will be available until July 16, 2026.Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUA865. CME/MOC/AAPA/IPCE credit will be available until July 16, 2026.Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Today on Raise the Line, we bring you the unlikely and inspiring story of a woman who was afraid of blood as a child but became an accomplished nurse; who struggled with learning disabilities but became an effective educator; and who, despite lacking business experience or knowledge of graphics, built a successful company that produces visually rich educational materials for nurses and other providers. “I think the theme of my life has been I have struggled with learning, and I didn't want other people to struggle,” says Jennifer Zahourek, RN, the founder and CEO of RekMed which has developed a sequential, interactive learning system that includes illustrated planners, books, and videos used by millions of students and providers. The initial focus was to provide nurses with everything they needed to know from “the basics to the bedside” but RekMed now offers content for medics, respiratory therapists, medical assistants, and veterinarians as well. Driven by her belief in the power of visual learning and her “just freakin' do it” attitude, Jennifer overcame her fear of launching a business and quickly realized just how well nursing had prepared her for the hard work and unpredictability of entrepreneurship. “Nursing teaches you how to just be resilient, to pivot, to delegate, to work on a team and to handle high stress. I think nurses could literally be some of the best entrepreneurs on the planet,” she tells host Lindsey Smith. Tune in to this lively and valuable conversation as Jennifer shares lessons from bootstrapping a publishing company, insights on the evolving landscape of healthcare education, and advice on embracing change in nursing, especially with the expanding role of AI. Mentioned in this episode:RekMed If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

In this episode of Decoding Destiny: Navigating Breast Cancer with Genetic Insight, I'm joined by Dena Goldberg, board-certified genetic counselor and founder of Malibu Genetics. We talk about the critical role genetic counselors play in assessing breast cancer risk, and how genetic testing can guide treatment and preventive care. Dena also shares how she supports patients through the emotional impact of receiving test results—and how understanding your genetic risk can be both empowering and life-saving. We also look ahead at the future of genetic testing, including the promise of population screening and the ongoing push for more equitable access. Listen now to learn how genetic counseling can help you and your loved ones make informed, proactive decisions about breast cancer risk.  Special thanks to AstraZeneca and Merck for making this episode possible.

Dave Rubin of “The Rubin Report” talks about Bill Nye's attempt to convince CNN's Dana Bash of his simplistic solution to extreme weather events like the catastrophic flooding of the Guadalupe River that affected Kerrville, Texas; Sean Gunn and James Gunn's pathetic attempt to inject woke politics into the new Superman movie, by labeling Superman an immigrant; Fox News' Jesse Watters sharing mindblowing clips of Joe Biden's doctor, Kevin O'Connor, pleading the fifth repeatedly when asked about his knowledge of Joe Biden's cognitive decline; host of “SubwayTakes”, Kareem Rahma, admitting that his Kamala Harris interview had to be scrapped because her performance was so terrible he thought it might cost her the election; CNN's Wolf Blitzer confronting Hakeem Jeffries with rumors that supporters of Zohran Mamdani are plotting to primary him; Scott Jennings's perfect common sense response to the New York Times' Lulu Garcia-Navarro's freak out over work requirements for Medicaid; Elon Musk's massive claims about the brilliance of Grok 4 as controversy erupts over Grok's recent antisemitic outburst praising Hitler and CEO Linda Yaccarino stepping down; “The View's” Whoopi Goldberg freaking out over AI and technological progress; and much more. Dave also does a special “ask me anything” question-and-answer session on a wide-ranging host of topics, answering questions from the Rubin Report Locals community. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Check out the NEW RUBIN REPORT MERCH here: https://daverubin.store/ ----------  Today's Sponsors: Ultimate Base Spike Detox Trio - Fight the negative effects of the AstraZeneca vaccine with Dr. McCullough's protocol. Save 15% and get free shipping. Go to: https://TWC.health/RUBIN and use CODE: RUBIN Rumble Premium - Corporate America is fighting to remove speech, Rumble is fighting to keep it. If you really believe in this fight Rumble is offering $10 off with the promo code RUBIN when you purchase an annual subscription. Go to: https://Rumble.com/premium/RUBIN and use promo code RUBIN 1775 Coffee - 1775's Peaberry Coffee will give you more mental clarity, better energy and zero crash. Rubin Report viewers get 15% off their order. Go to: https://1775coffee.com/RUBIN and use code RUBIN